Great article, and it highlights how undervalued IHL is with 6 development programs underway and potentially a second psychedelics program as well. All the value is created by IP, that’s crystal clear and progressing rapidly.
GW Pharma has been acquired by NASDAQ listed Jazz Pharma for US$7.2 billion (A$9 billion). They have one flagship CBD drug, Epidiolex which we’ve discussed on this thread.
MindMed is now US$1.4 billion (A$1.8 billion) with a psychedelics program.
What could IHL could be valued at on the NASDAQ?
IHL Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held
